Advanced search
Publication Cover
Future Medicinal Chemistry Volume 15, 2023 - Issue 19
Submit an article Journal homepage
205
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Targeted Covalent Inhibitors for Novel Therapeutics

Jingya Zhang2 School of Pharmaceutical SciencesZhengzhou UniversityZhengzhou450001ChinaORCID Iconhttps://orcid.org/0009-0003-3861-7540
ORCID Icon,
Wenshuo Gao2 School of Pharmaceutical SciencesZhengzhou UniversityZhengzhou450001China
,
Yixia Wang2 School of Pharmaceutical SciencesZhengzhou UniversityZhengzhou450001China
,
Junbiao Chang1 College of ChemistryZhengzhou UniversityZhengzhou450001China;2 School of Pharmaceutical SciencesZhengzhou UniversityZhengzhou450001China;3 Pingyuan LaboratoryState Key Laboratory of Antiviral DrugsHenan Normal UniversityXinxiang453007ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6236-1256
ORCID Icon &
Bin Yu1 College of ChemistryZhengzhou UniversityZhengzhou450001China;2 School of Pharmaceutical SciencesZhengzhou UniversityZhengzhou450001China;3 Pingyuan LaboratoryState Key Laboratory of Antiviral DrugsHenan Normal UniversityXinxiang453007ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7207-643X
ORCID Icon
Pages 1739-1741 | Received 17 Aug 2023, Accepted 22 Aug 2023, Published online: 04 Oct 2023

References

  • Tuley A , FastW. The taxonomy of covalent inhibitors. Biochemistry57(24), 3326–3337 (2018).
  • Boike L , HenningNJ , NomuraDK. Advances in covalent drug discovery. Nat. Rev. Drug Discov.21(12), 881–898 (2022).
  • Kim H , HwangYS , KimM , ParkSB. Recent advances in the development of covalent inhibitors. RSC Med. Chem.12(7), 1037–1045 (2021).
  • Nicola G , TombergJ , PrattRFet al. Crystal structures of covalent complexes of β-lactam antibiotics with Escherichia coli penicillin-binding protein 5: toward an understanding of antibiotic specificity. Biochemistry49(37), 8094–8104 (2010).
  • Lonsdale R , WardRA. Structure-based design of targeted covalent inhibitors. Chem. Soc. Rev.47(11), 3816–3830 (2018).
  • Gehringer M , LauferSA. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J. Med. Chem.62(12), 5673–5724 (2019).
  • Lu X , SmaillJB , PattersonAV , DingK. Discovery of cysteine-targeting covalent protein kinase inhibitors. J. Med. Chem.65(1), 58–83 (2022).
  • Jones LH . Design of next-generation covalent inhibitors: targeting residues beyond cysteine. Annu. Rep. Med. Chem.56, 95–134 (2021).
  • Lagoutte R , PatouretR , WinssingerN. Covalent inhibitors: an opportunity for rational target selectivity. Curr. Opin. Chem. Biol.39, 54–63 (2017).
  • Fu K , XieF , WangF , FuL. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J. Hematol. Oncol.15(1), 173 (2022).
  • Huang L , GuoZ , WangF , FuL. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther.6(1), 386 (2021).
  • Lanman BA , AllenJR , AllenJGet al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J. Med. Chem.63(1), 52–65 (2020).
  • Péczka N , OrgovánZ , Ábrányi-BaloghP , KeserűGM. Electrophilic warheads in covalent drug discovery: an overview. Expert Opin. Drug Discov.17(4), 413–422 (2022).
  • Song Z , GeY , WangCet al. Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer. J. Med. Chem.59(14), 6580–6594 (2016).
  • Chen L , FuW , ZhengLet al. Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer. J. Med. Chem.61(10), 4290–4300 (2018).
  • Strelow JM . A perspective on the kinetics of covalent and irreversible inhibition. SLAS Discov.22(1), 3–20 (2017).
  • Barf T , KapteinA. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem.55(14), 6243–6262 (2012).
  • Zhao Z , BournePE. Progress with covalent small-molecule kinase inhibitors. Drug Discov. Today23(3), 727–735 (2018).
  • Owen DR , AllertonCMN , AndersonASet al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science374(6575), 1586–1593 (2021).
  • Faridoon , NgR , ZhangG , LiJJ. An update on the discovery and development of reversible covalent inhibitors. Med. Chem. Res.32(6), 1039–1062 (2023).
  • Lu D , YuX , LinHet al. Applications of covalent chemistry in targeted protein degradation. Chem. Soc. Rev.51(22), 9243–9261 (2022).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.